S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

GDTC CytoMed Therapeutics Ltd

2.75

-0.06 (-2.14%)

Mar 04 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

CytoMed Therapeutics (NASDAQ:GDTC)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more CytoMed Therapeutics Charts.

CytoMed Therapeutics (NASDAQ:GDTC)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more CytoMed Therapeutics Charts.

CytoMed Therapeutics Ltd News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Tuesday 4 March 2025 (6 hours ago) • Edgar (US Regulatory)

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
Thursday 6 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Monday 6 January 2025 (2 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 6 January 2025 (2 months ago) • Edgar (US Regulatory)

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
Monday 6 January 2025 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 5 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 20 November 2024 (3 months ago) • Edgar (US Regulatory)

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Wednesday 20 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Monday 4 November 2024 (4 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 7 October 2024 (5 months ago) • Edgar (US Regulatory)

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
Monday 7 October 2024 (5 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 3 October 2024 (5 months ago) • Edgar (US Regulatory)

More CytoMed Therapeutics Ltd News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions